Investment
Features
FeesSafety
Academy
More
Pluang+

Evergy rated Buy with 10%+ annual returns potential, backed by strong growth and dividend safety.

Analyst Insights
18 Sep 2026
Seeking Alpha
View Source
Bullish
Evergy rated Buy with 10%+ annual returns potential, backed by strong growth and dividend safety.

Evergy, Inc. is maintained at a Buy rating, trading at a slight discount to its fair value, with potential for double-digit annual total returns. The company benefits from a strong pipeline of data center-driven energy service agreements and regulatory support, enabling high single-digit adjusted earnings growth through 2030 and beyond. Its solid BBB+ credit rating, stable cash flow metrics, and sustainable dividend payout ratio ensure dividend safety and capacity for future capital investments. Despite modest dividend growth forecasts, Evergy's near Dividend Aristocrat status and disciplined capital spending position it well for over 10% annual total returns in the coming decade.

Evergy's dividend growth outlook is provided here alongside Pluang's Utilities sector data as of Sep 18, 2026 17:42 WIB. Among 20 US utilities stocks on Pluang, 8 rose and 10 fell today. Entergy Corporation (ETR) gained 0.58% to USD 103.91 with a typical hold time of 2 days, while Sempra Energy (SRE) declined 0.54% to USD 81.78 despite 95% buy order activity and a 0-day hold time. NRG Energy Inc (NRG) rose 0.44% to USD 106.70 with a notably longer typical hold time of 62 days and 100% buy orders.

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
1 hour ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
2 hours ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
2 hours ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
3 hours ago
Bitcoin surges past $80K as $183M in short bets liquidate, fueling a sharp price rally.

Bitcoin surges past $80K as $183M in short bets liquidate, fueling a sharp price rally.

Bitcoin's price surged from around $76,400 to nearly $81,000 on September 18, 2026, driven by a rapid liquidation of $192 million in leveraged crypto positions, including $183 million in short bets. This forced buying pushed Bitcoin above $80,000 for...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App